Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Maaike van Putten

Showing results (1-10 of 61) with videos related to

Pageof 7
Sort By:
Disease Models & Mechanisms|August 1, 2022
The predictive value of models of neuromuscular disorders to potentiate clinical translationMaaike van Putten
Expert Opinion on Biological Therapy|April 23, 2011
Opportunities and challenges for the development of antisense treatment in neuromuscular disordersMaaike van Putten, Annemieke Aartsma-Rus
Disease Models & Mechanisms|October 9, 2019
The use of genetically humanized animal models for personalized medicine approachesAnnemieke Aartsma-Rus, Maaike van Putten
Journal of Visualized Experiments : Jove|April 22, 2014
Assessing functional performance in the mdx mouse modelAnnemieke Aartsma-Rus, Maaike van Putten
Journal of Neuromuscular Diseases|January 8, 2024
Antisense Oligonucleotide-Mediated Downregulation of IGFBPs Enhances IGF-1 SignalingAlper Yavas, Maaike van Putten, Annemieke Aartsma-Rus
Disease Models & Mechanisms|August 1, 2025
Understanding Duchenne muscular dystrophy-associated brain pathologyMinou A T Verhaeg, Rosanne Govaarts, Maaike van Putten
Neuromuscular Disorders : NMD|June 1, 2025
Antisense oligonucleotide-mediated redirection of Igf1 alternative polyadenylationAlper Yavas, Maaike van Putten, Yavuz Ariyurek, et al.
Disease Models & Mechanisms|April 1, 2020
Moving neuromuscular disorders research forward: from novel models to clinical studiesMaaike van Putten, Julija Hmeljak, Annemieke Aartsma-Rus, et al.
Journal of Neuromuscular Diseases|November 7, 2022
On the use of D2.B10-Dmdmdx/J (D2.mdx) Versus C57BL/10ScSn-Dmdmdx/J (mdx) Mouse Models for Preclinical Studies on Duchenne Muscular Dystrophy: A Cautionary Note from Members of the TREAT-NMD Advisory Committee on TherapeuticsAnnemieke Aartsma-Rus, Maaike van Putten, Paola Mantuano, et al.
Frontiers in Behavioral Neuroscience|February 8, 2021
Assessment of Behavioral Characteristics With Procedures of Minimal Human Interference in the <i>mdx</i> Mouse Model for Duchenne Muscular DystrophySarah Engelbeen, Annemieke Aartsma-Rus, Bastijn Koopmans, et al.
Pageof 7

Showing results (1-10 of 61) with videos related to

Sort By:
Pageof 7
Disease Models & Mechanisms|August 1, 2022
The predictive value of models of neuromuscular disorders to potentiate clinical translationMaaike van Putten
Expert Opinion on Biological Therapy|April 23, 2011
Opportunities and challenges for the development of antisense treatment in neuromuscular disordersMaaike van Putten, Annemieke Aartsma-Rus
Disease Models & Mechanisms|October 9, 2019
The use of genetically humanized animal models for personalized medicine approachesAnnemieke Aartsma-Rus, Maaike van Putten
Journal of Visualized Experiments : Jove|April 22, 2014
Assessing functional performance in the mdx mouse modelAnnemieke Aartsma-Rus, Maaike van Putten
Journal of Neuromuscular Diseases|January 8, 2024
Antisense Oligonucleotide-Mediated Downregulation of IGFBPs Enhances IGF-1 SignalingAlper Yavas, Maaike van Putten, Annemieke Aartsma-Rus
Disease Models & Mechanisms|August 1, 2025
Understanding Duchenne muscular dystrophy-associated brain pathologyMinou A T Verhaeg, Rosanne Govaarts, Maaike van Putten
Neuromuscular Disorders : NMD|June 1, 2025
Antisense oligonucleotide-mediated redirection of Igf1 alternative polyadenylationAlper Yavas, Maaike van Putten, Yavuz Ariyurek, et al.
Disease Models & Mechanisms|April 1, 2020
Moving neuromuscular disorders research forward: from novel models to clinical studiesMaaike van Putten, Julija Hmeljak, Annemieke Aartsma-Rus, et al.
Journal of Neuromuscular Diseases|November 7, 2022
On the use of D2.B10-Dmdmdx/J (D2.mdx) Versus C57BL/10ScSn-Dmdmdx/J (mdx) Mouse Models for Preclinical Studies on Duchenne Muscular Dystrophy: A Cautionary Note from Members of the TREAT-NMD Advisory Committee on TherapeuticsAnnemieke Aartsma-Rus, Maaike van Putten, Paola Mantuano, et al.
Frontiers in Behavioral Neuroscience|February 8, 2021
Assessment of Behavioral Characteristics With Procedures of Minimal Human Interference in the <i>mdx</i> Mouse Model for Duchenne Muscular DystrophySarah Engelbeen, Annemieke Aartsma-Rus, Bastijn Koopmans, et al.
Pageof 7